 | • レポートコード：MRC2304F182 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、224ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に200.4億ドルであった世界の子宮がん治療＆診断市場規模は2022年に212.5億ドルになり、更に年平均6.19％拡大して2027年までに287.5億ドルに達する見通しです。本書は、子宮がん治療＆診断の世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、がんタイプ別（腺扁平上皮がん、子宮内膜腺がん、乳頭漿液性がん、子宮肉腫）分析、製品別（子宮がん診断、子宮がん治療）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめた市場調査レポートです。なお、本書に掲載されている企業情報には、Abbott Laboratories、AbbVie Inc、Ability Pharma、Allergan, Inc.、Apotex Inc.、ARIAD Pharmaceuticals, Inc、AstraZeneca、Becton Dickinson and Company、BioMerieux SA、Danaher Corporation、Elekta AB (pub)、Eli Lilly and Companyなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の子宮がん治療＆診断市場規模：がんタイプ別 - 腺扁平上皮がんの市場規模 - 子宮内膜腺がんの市場規模 - 乳頭漿液性がんの市場規模 - 子宮肉腫の市場規模 ・世界の子宮がん治療＆診断市場規模：製品別 - 子宮がん診断の市場規模 - 子宮がん治療の市場規模 ・世界の子宮がん治療＆診断市場規模：地域別 - 南北アメリカの子宮がん治療＆診断市場規模 アメリカの子宮がん治療＆診断市場規模 カナダの子宮がん治療＆診断市場規模 ブラジルの子宮がん治療＆診断市場規模 ... - アジア太平洋の子宮がん治療＆診断市場規模 日本の子宮がん治療＆診断市場規模 中国の子宮がん治療＆診断市場規模 インドの子宮がん治療＆診断市場規模 韓国の子宮がん治療＆診断市場規模 台湾の子宮がん治療＆診断市場規模 ... - ヨーロッパ/中東/アフリカの子宮がん治療＆診断市場規模 イギリスの子宮がん治療＆診断市場規模 ドイツの子宮がん治療＆診断市場規模 フランスの子宮がん治療＆診断市場規模 ロシアの子宮がん治療＆診断市場規模 ... - その他地域の子宮がん治療＆診断市場規模 ・競争状況 ・企業情報 |
The Global Uterine Cancer Therapeutics & Diagnostics Market size was estimated at USD 20.04 billion in 2021 and expected to reach USD 21.25 billion in 2022, and is projected to grow at a CAGR 6.19% to reach USD 28.75 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Uterine Cancer Therapeutics & Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Cancer Type, the market was studied across Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma.
Based on Product, the market was studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biopsy, CT Scan, Dilation and Curettage, Hysteroscopy, and Pelvic Ultrasound. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Surgery.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Uterine Cancer Therapeutics & Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Uterine Cancer Therapeutics & Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Uterine Cancer Therapeutics & Diagnostics Market, including Abbott Laboratories, AbbVie Inc, Ability Pharma, Allergan, Inc., Apotex Inc., ARIAD Pharmaceuticals, Inc, AstraZeneca, Becton Dickinson and Company, BioMerieux SA, Danaher Corporation, Elekta AB (pub), Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC., Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Uterine Cancer Therapeutics & Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Uterine Cancer Therapeutics & Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Uterine Cancer Therapeutics & Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Uterine Cancer Therapeutics & Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Uterine Cancer Therapeutics & Diagnostics Market?
6. What is the market share of the leading vendors in the Global Uterine Cancer Therapeutics & Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Uterine Cancer Therapeutics & Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness of uterine cancer in physicians and healthcare providers
5.1.1.2. Rising in importance of the women health
5.1.1.3. Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
5.1.2. Restraints
5.1.2.1. Expensive treatment methods along with adverse side effects and severe toxicity of the medications
5.1.3. Opportunities
5.1.3.1. Increasing advancements in the cancer screening and treatment methods
5.1.3.2. Developing countries organising various programmes about uterine cancer severity and importance
5.1.4. Challenges
5.1.4.1. Low success rate of cancer drug clinical trials
5.2. Cumulative Impact of COVID-19
6. Uterine Cancer Therapeutics & Diagnostics Market, by Cancer Type
6.1. Introduction
6.2. Adenosquamous Carcinoma
6.3. Endometrial Adenocarcinoma
6.4. Papillary Serous Carcinoma
6.5. Uterine Sarcoma
7. Uterine Cancer Therapeutics & Diagnostics Market, by Product
7.1. Introduction
7.2. Diagnostics
7.3.1. Biopsy
7.3.2. CT Scan
7.3.3. Dilation and Curettage
7.3.4. Hysteroscopy
7.3.5. Pelvic Ultrasound
7.3. Therapeutics
7.4.1. Chemotherapy
7.4.2. Immunotherapy
7.4.3. Radiation Therapy
7.4.4. Surgery
8. Americas Uterine Cancer Therapeutics & Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. AbbVie Inc
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Ability Pharma
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Allergan, Inc.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Apotex Inc.
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. ARIAD Pharmaceuticals, Inc
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. AstraZeneca
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Becton Dickinson and Company
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. BioMerieux SA
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Danaher Corporation
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Elekta AB (pub)
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Eli Lilly and Company
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. F. Hoffmann-La Roche AG
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. GlaxoSmithKline PLC.
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Johnson & Johnson Services, Inc
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Merck & Co., Inc.
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Novartis AG
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Pfizer Inc.
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Sanofi S.A.
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Siemens Healthineers AG
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Takeda Pharmaceutical Company Limited
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. Teva Pharmaceutical Industries Ltd.
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing